Page last updated: 2024-08-22

platinum and regorafenib

platinum has been researched along with regorafenib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	3 (100.00)	2.80

Authors

Authors	Studies
Borbath, I; Delaunoit, T; Demols, A; Goemine, JC; Holbrechts, S; Houbiers, G; Laurent, S; Marechal, R; Paesmans, M; Peeters, M; Van den Eynde, M; Van Laethem, JL	1
Lamarca, A; Valle, JW	1
Abdeddaim, C; Anota, A; Brocard, F; Cancel, M; Floquet, A; Frenel, JS; Hardy-Bessard, AC; Houlier, A; Kalbacher, E; Lardy-Cleaud, A; Largillier, R; Levaché, CB; Lortholary, A; Louvet, C; Meunier, J; Mouret-Reynier, MA; Pissaloux, D; Pop, O; Provansal, M; Ray-Coquard, I; Savoye, AM; Trédan, O; Treilleux, I; Venat-Bouvet, L; You, B; Zannetti, A	1

Trials

2 trial(s) available for platinum and regorafenib

Article	Year
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Phenylurea Compounds; Platinum; Pyridines; Treatment Outcome	2020
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR). Gynecologic oncology, 2022, Volume: 164, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phenylurea Compounds; Platinum; Pyridines; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Treatment Outcome	2022

Article

Year

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9

Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Phenylurea Compounds; Platinum; Pyridines; Treatment Outcome

2020

Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).

Gynecologic oncology, 2022, Volume: 164, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phenylurea Compounds; Platinum; Pyridines; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Treatment Outcome

2022

Other Studies

1 other study(ies) available for platinum and regorafenib

Article	Year
Reaching out beyond first-line treatments in advanced biliary tract cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Phenylurea Compounds; Platinum; Pyridines	2020